tradingkey.logo

OmniAb Inc

OABI
View Detailed Chart

1.634USD

+0.014+0.88%
Market hours ETQuotes delayed by 15 min
200.53MMarket Cap
LossP/E TTM

OmniAb Inc

1.634

+0.014+0.88%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.88%

5 Days

+4.10%

1 Month

-18.69%

6 Months

-48.44%

Year to Date

-53.83%

1 Year

-64.32%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
83 / 507
Overall Ranking
196 / 4723
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
7.857
Target Price
+388.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Growing
The company is in a growing phase, with the latest annual income totaling USD 26.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 177.75.
Overvalued
The company’s latest PE is -2.68, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 92.68M shares, decreasing 5.93% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 5.27M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.18.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Ticker SymbolOABI
CompanyOmniAb Inc
CEOMr. Matthew William (Matt) Foehr
Websitehttps://www.omniab.com/
KeyAI